Paolo Manganotti Selected Research

Deep Brain Stimulation

1/2014	Deep brain stimulation in persistent vegetative States: ethical issues governing decision making.
1/2011	Behavioral and neurophysiological effects of repetitive transcranial magnetic stimulation on the minimally conscious state: a case study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paolo Manganotti Research Topics

Disease

33	Stroke (Strokes) 03/2024 - 04/2008
13	Ischemic Stroke 12/2022 - 08/2018
10	COVID-19 03/2024 - 01/2020
8	Parkinson Disease (Parkinson's Disease) 01/2023 - 12/2002
6	Cognitive Dysfunction 03/2024 - 11/2020
6	Pain (Aches) 01/2023 - 07/2010
6	Multiple Sclerosis 12/2022 - 02/2018
6	Seizures (Absence Seizure) 10/2021 - 08/2009
5	Status Epilepticus (Complex Partial Status Epilepticus) 03/2024 - 12/2018
5	Headache (Headaches) 01/2024 - 10/2016
5	Epilepsy (Aura) 11/2020 - 01/2013
5	Persistent Vegetative State (Vegetative State) 01/2019 - 01/2011
4	Neurodegenerative Diseases (Neurodegenerative Disease) 06/2022 - 01/2019
3	Intracranial Hemorrhages (Intracranial Hemorrhage) 03/2023 - 09/2019
3	Infections 01/2023 - 09/2019
3	Nervous System Diseases (Neurological Disorders) 01/2023 - 04/2013
3	Encephalitis (Encephalitis, Rasmussen) 01/2023 - 10/2020
3	Disease Progression 01/2022 - 11/2002
3	Migraine Disorders (Migraine) 01/2022 - 07/2012
3	Alzheimer Disease (Alzheimer's Disease) 11/2021 - 01/2019
3	Cerebellar Diseases (Cerebellar Syndrome) 02/2004 - 04/2003
2	Mental Fatigue 05/2023 - 01/2023
2	Stuttering (Stammering) 01/2023 - 01/2016
2	Muscular Diseases (Myopathy) 01/2023 - 07/2017
2	Post-Acute COVID-19 Syndrome 01/2023 - 10/2022
2	Polyneuropathies (Polyneuropathy) 01/2023 - 02/2018
2	Orthostatic Hypotension (Postural Hypotension) 06/2022 - 02/2022
2	Disruptive, Impulse Control, and Conduct Disorders (Kleptomania) 03/2022 - 01/2018
2	Synucleinopathies 01/2022 - 01/2021
2	Spasm (Spasms) 12/2021 - 02/2013
2	Inflammation (Inflammations) 09/2021 - 09/2016
2	Infarction (Infarctions) 11/2020 - 03/2020
2	Fatigue 11/2020 - 07/2008
2	Neurobehavioral Manifestations 10/2020 - 01/2019
2	Limbic Encephalitis (Paraneoplastic Limbic Encephalitis) 10/2020 - 05/2019
2	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2020 - 07/2008
2	Consciousness Disorders 01/2020 - 01/2019
2	Muscle Spasticity (Spastic) 01/2014 - 03/2007
2	Meniere Disease (Menieres Disease) 01/2014 - 07/2011
1	Neuroinflammatory Diseases 03/2024
1	Ageusia (Hypogeusia) 01/2023
1	Contracture 01/2023
1	Anosmia 01/2023
1	Hemorrhage 12/2022
1	Neutropenia 12/2022
1	Deglutition Disorders (Dysphagia) 10/2022

Drug/Important Bio-Agent (IBA)

11	Cytidine Triphosphate (CTP)IBA 10/2021 - 08/2018
9	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2018
7	Type A Botulinum Toxins (Botox)FDA Link 01/2023 - 03/2007
6	Botulinum Toxins (Botulinum Toxin)IBA 01/2023 - 03/2007
4	SynucleinsIBA 08/2022 - 01/2019
4	Proteins (Proteins, Gene)FDA Link 01/2020 - 02/2018
3	Intravenous Immunoglobulins (IVIG)FDA Link 01/2023 - 01/2020
3	AntibodiesIBA 03/2022 - 05/2019
3	Tissue Plasminogen Activator (Alteplase)FDA Link 11/2020 - 09/2019
3	salicylhydroxamic acid (SHAM)IBA 11/2020 - 02/2007
3	Anticonvulsants (Antiepileptic Drugs)IBA 10/2020 - 07/2014
2	AntioxidantsIBA 03/2024 - 06/2022
2	incobotulinumtoxinA FDA Link 01/2023 - 06/2010
2	Neurotransmitter Agents (Neurotransmitter)IBA 01/2023 - 11/2002
2	Rituximab (Mabthera)FDA Link 12/2022 - 10/2020
2	hydroxide ionIBA 06/2022 - 02/2022
2	Antidepressive Agents (Antidepressants)IBA 06/2022 - 01/2022
2	SolutionsIBA 06/2022 - 01/2021
2	Bortezomib (Velcade)FDA Link 01/2021 - 07/2017
2	Dopamine (Intropin)FDA LinkGeneric 11/2020 - 01/2018
2	DNA-Binding Proteins (DNA Binding Protein)IBA 01/2020 - 01/2019
2	PrionsIBA 01/2020 - 01/2019
2	Levodopa (L Dopa)FDA LinkGeneric 01/2018 - 01/2009
2	TESIBA 04/2003 - 12/2002
1	LuteolinIBA 03/2024
1	co-ultraPEALutIBA 03/2024
1	TroponinIBA 01/2024
1	AlbuminsIBA 03/2023
1	C-Reactive ProteinIBA 03/2023
1	SARS-CoV-2 spike proteinIBA 01/2023
1	LectinsIBA 01/2023
1	Complement System Proteins (Complement)IBA 01/2023
1	3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)IBA 01/2023
1	Oxidoreductases (Dehydrogenase)IBA 01/2023
1	Mannose-Binding Lectin (Mannan-Binding Lectin)IBA 01/2023
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 12/2022
1	Fibrinogen (Factor I)FDA Link 12/2022
1	ocrelizumabIBA 12/2022
1	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 12/2022
1	Hemoglobins (Hemoglobin)IBA 12/2022

Therapy/Procedure

19	Therapeutics 01/2024 - 03/2007
18	Transcranial Magnetic Stimulation 05/2023 - 12/2002
7	Transcranial Direct Current Stimulation 01/2023 - 12/2002
5	Thrombectomy 03/2024 - 07/2018
3	Extracorporeal Shockwave Therapy 01/2014 - 04/2010
2	Activities of Daily Living (ADL) 01/2023 - 01/2020
2	Immunotherapy 03/2022 - 01/2021
2	Physical Therapy Modalities (Physical Therapy Technique) 01/2022 - 01/2019
2	Injections 12/2021 - 02/2013
2	Aftercare (After-Treatment) 07/2017 - 07/2010
2	Deep Brain Stimulation 01/2014 - 01/2011
2	Denervation 01/2014 - 07/2011
1	Enteral Nutrition (Feeding, Tube) 10/2022
1	Ambulatory Care (Outpatient Care) 10/2022